Clinical Trial Update: Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for a single-bolus non-immunogenic staphylokinase being studied for acute ischemic stroke, with administration 4.5-24 hours after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Staphylokinase (staphylokinase)

Snippet

Sponsor: Supergene, LLC | Conditions: Ischemic Stroke, Acute | Phase 3 | Status: NOT_YET_RECRUITING